%0 Journal Article
%T Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease
%A Aamir Ali Asgar Syed
%A Bader Unnisa
%A Md Nematullah Khan
%A Ruheena Yasmeen
%A Syed Ibrahim Hassan
%A Syeda Zaineb Humaira Hussaini
%A Syeda Zaineb Kubra Hussaini
%J Archive of "Perspectives in Clinical Research".
%D 2018
%R 10.4103/picr.PICR_99_16
%X Helicobacter pylori, the cause of most peptic ulcer diseases, infects approximately 50% of the population worldwide. Indian data on cost and effectiveness of the standard first-line therapies for H. pylori eradication are scarce. Thus, the present study was aimed at comparing the cost and efficacy of two standard first-line therapies: Regimen I comprising pantoprazole (40 mg) plus amoxicillin (750 mg) plus clarithromycin (500 mg) (PAC) and Regimen II comprising rabeprazole (20 mg) plus amoxicillin (625 mg) plus metronidazole (200 mg) (RAM)
%K Cost-effectiveness analysis
%K Helicobacter pylori
%K peptic ulcer disease
%K perspective
%K pharmacoeconomics
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799951/